All Stories

  1. Utilization of Lung Cancer Registries in Learning Health Systems for Health Care Improvement
  2. Effective management of incidental findings in lung cancer screening: the role of the screening review meeting
  3. Increasing Lung Screening uptake: Exploring people who smoke and their family members concerns and recommendations regarding screening invitations
  4. Explainable Boosting Machines for Lung Cancer Prediction and Explanation
  5. Decision Tree Models to Select High-Risk Patients for Lung Cancer Screening and Model Interpretability
  6. Achieving earlier diagnosis of symptomatic lung cancer
  7. Quality assurance in lung cancer screening
  8. Pulmonary fibrosis and lung cancer: an analysis of the Clinical Practice Research Datalink linked to the National Cancer Registration Dataset
  9. The importance of co-located, high intensity smoking cessation support within lung cancer screening: Findings from the Process Evaluation of the Yorkshire Enhanced Stop Smoking study
  10. Uptake and 4-week quit rates from an opt-out co-located smoking cessation service delivered alongside community-based low-dose computed tomography screening within the Yorkshire Lung Screening Trial
  11. Impact of the SARS-CoV-2 pandemic on lung cancer survival in England: an analysis of the rapid cancer registration dataset
  12. Measuring Harms of Lung Cancer Screening
  13. Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven other risk prediction models
  14. Measuring spirometry in a lung cancer screening cohort highlights possible underdiagnosis and misdiagnosis of COPD
  15. The Impact of COVID-19 on Lung Cancer Incidence in England
  16. Developing a pan-European technical standard for a comprehensive high-quality lung cancer computed tomography screening programme: an ERS technical standard
  17. Defining the road map to a UK national lung cancer screening programme
  18. Recalibration of a Deep Learning Model for Low-Dose Computed Tomographic Images to Inform Lung Cancer Screening Intervals
  19. Lung cancer screening
  20. Lung nodules: sorting the wheat from the chaff
  21. Clinical trials in cancer screening, prevention and early diagnosis (SPED): A systematic mapping review
  22. Important parameters for cost-effective implementation of lung cancer screening
  23. Decision Tree Approaches to Select High Risk Patients for Lung Cancer Screening Based on the UK Primary Care Data
  24. Logistic Regression Approach to a Joint Classification and Feature Selection in Lung Cancer Screening Using CPRD Data
  25. Co-development of an evidence-based personalised smoking cessation intervention for use in a lung cancer screening context
  26. European Respiratory Society guideline on various aspects of quality in lung cancer care
  27. Impact of radiographer immediate reporting of X-rays of the chest from general practice on the lung cancer pathway (radioX): a randomised controlled trial
  28. An International Consensus on Actions to Improve Lung Cancer Survival: A Modified Delphi Method Among Clinical Experts in the International Cancer Benchmarking Partnership
  29. Decision Support Tools for Low-Dose CT Lung Cancer Screening
  30. Co-development of an evidence-based personalised smoking cessation intervention for use in a lung cancer screening context
  31. Participation in community-based lung cancer screening: the Yorkshire Lung Screening Trial
  32. Predicting the future risk of lung cancer: development and validation of QCancer2 (10-year risk) lung model and evaluating the model performance of nine prediction models
  33. Acceptability of a standalone written leaflet for the National Health Service for England Targeted Lung Health Check Programme: A concurrent, think‐aloud study
  34. The role of computer-assisted radiographer reporting in lung cancer screening programmes
  35. Attitudes towards the integration of smoking cessation into lung cancer screening in the United Kingdom: A qualitative study of individuals eligible to attend
  36. Implementing Lung Cancer Screening in Europe: Taking a Systems Approach
  37. Ninety-day mortality following lung cancer surgery: outcomes from the English national clinical outcomes audit
  38. Lung Cancer in the United Kingdom
  39. Management of Lung Cancer Screening Results Based on Individual Prediction of Current and Future Lung Cancer Risks
  40. The Future of Lung Cancer Screening: Current Challenges and Research Priorities
  41. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study
  42. Analysis of the baseline performance of five UK lung cancer screening programmes
  43. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis
  44. Selection of eligible participants for screening for lung cancer using primary care data
  45. What is the Definition of Cure in Non-small Cell Lung Cancer?
  46. International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study
  47. Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial)
  48. Correction: Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom
  49. Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom
  50. Factors associated with survival in small cell lung cancer: an analysis of real-world national audit, chemotherapy and radiotherapy data
  51. Participation in lung cancer screening
  52. Importance of research design in biomarkers for lung cancer
  53. Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation
  54. Selecting Lung Cancer Patients from UK Primary Care Data: A Longitudinal Study of Feature Trends
  55. Reply to Wilson: Improving Lung Cancer Screening Uptake
  56. Pulmonary nodules
  57. New fissure-attached nodules in lung cancer screening: more practical implications from the NELSON study?
  58. An update on CT screening for lung cancer: the first major targeted cancer screening programme
  59. Yorkshire Enhanced Stop Smoking (YESS) study: a protocol for a randomised controlled trial to evaluate the effect of adding a personalised smoking cessation intervention to a lung cancer screening programme
  60. Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk
  61. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer
  62. Lung Screen Uptake Trial: results from a single lung cancer screening round
  63. Targeted screening for lung cancer is here but who do we target and how?
  64. SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection
  65. Prevalence, Symptom Burden, and Underdiagnosis of Chronic Obstructive Pulmonary Disease in a Lung Cancer Screening Cohort
  66. Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe
  67. Lung Screen Uptake Trial (LSUT): Randomized Controlled Clinical Trial Testing Targeted Invitation Materials
  68. Lung cancer: investigation and staging
  69. External validation of a convolutional neural network artificial intelligence tool to predict malignancy in pulmonary nodules
  70. A systematic review of survival following anti-cancer treatment for small cell lung cancer
  71. Post-treatment survival difference between lobectomy and stereotactic ablative radiotherapy in stage I non-small cell lung cancer in England
  72. Correction:Defining the information needs of lung cancer screening participants: a qualitative study
  73. Defining the information needs of lung cancer screening participants: a qualitative study
  74. Impact of choice of volumetry software and nodule management guidelines on recall rates in lung cancer screening
  75. Evaluation of cardiovascular risk in a lung cancer screening cohort
  76. Ex vivo Raman spectroscopy mapping of lung tissue: label-free molecular characterization of nontumorous and cancerous tissues
  77. Benefits and harms in the National Lung Screening Trial: expected outcomes with a modern management protocol
  78. Impact of a Lung Cancer Screening Information Film on Informed Decision-making: A Randomized Trial
  79. Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial
  80. Probability of cancer in lung nodules using sequential volumetric screening up to 12 months: the UKLS trial
  81. The potential of breath analysis to improve outcome for patients with lung cancer
  82. Status of Lung Cancer Data Collection in Europe
  83. Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries
  84. Lung cancer screening – gaining consensus on next steps – proceedings of a closed workshop in the UK
  85. Factors influencing treatment selection and 30-day mortality after chemotherapy for people with small-cell lung cancer: An analysis of national audit data
  86. ERS Statement on harmonised standards for lung cancer registration and lung cancer services in Europe
  87. EUPS—argues that lung cancer screening should be implemented in 18 months
  88. Lung cancer screening—low dose CT for lung cancer screening: recent trial results and next steps
  89. The continuum of screening and early detection, awareness and faster diagnosis of lung cancer
  90. Lung cancer in the UK: addressing geographical inequality and late diagnosis
  91. The Fleischner Society 2017 and British Thoracic Society 2015 guidelines for managing pulmonary nodules: keep calm and carry on
  92. British Thoracic Society quality standards for the investigation and management of pulmonary nodules
  93. Patient selection for future lung cancer computed tomography screening programmes: lessons learnt post National Lung Cancer Screening Trial
  94. Recent advances in the management of lung cancer
  95. Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients
  96. Low-dose CT for lung cancer screening – Authors' reply
  97. Low dose CT screening for lung cancer
  98. European position statement on lung cancer screening
  99. Impact of radiographer immediate reporting of chest X-rays from general practice on the lung cancer pathway (radioX): study protocol for a randomised control trial
  100. Treatment recommendations for stage I non-small cell lung cancer: does patient preference matter?
  101. Use of Volumetry for Lung Nodule Management: Theory and Practice
  102. Physician Assessment of Pretest Probability of Malignancy and Adherence to Guidelines for Pulmonary Nodule Evaluation
  103. Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial
  104. The impact of trained radiographers as concurrent readers on performance and reading time of experienced radiologists in the UK Lung Cancer Screening (UKLS) trial
  105. Lung cancer in symptomatic patients presenting in primary care: a systematic review of risk prediction tools
  106. Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study
  107. Socioeconomic position and delays in lung cancer diagnosis: should we target the more deprived?
  108. What is the Optimum Screening Strategy for the Early Detection of Lung Cancer
  109. Optimum low dose CT screening interval for lung cancer: the answer from NELSON?
  110. Comparing the performance of trained radiographers against experienced radiologists in the UK lung cancer screening (UKLS) trial
  111. Erratum to: The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with periphe...
  112. Implementation planning for lung cancer screening: five major challenges
  113. How should performance in EBUS mediastinal staging in lung cancer be measured?
  114. Place of Death in Patients with Lung Cancer: A Retrospective Cohort Study from 2004-2013
  115. Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial
  116. Defining a standard set of patient-centred outcomes for lung cancer
  117. Lung cancer risk in new pulmonary nodules: implications for CT screening and nodule management
  118. Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data
  119. Predicting death from surgery for lung cancer: A comparison of two scoring systems in two European countries
  120. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer
  121. Management of pulmonary nodules according to the 2015 British Thoracic Society guidelines. Key messages for clinical practice
  122. The Lung Screen Uptake Trial (LSUT): protocol for a randomised controlled demonstration lung cancer screening pilot testing a targeted invitation strategy for high risk and ‘hard-to-reach’ patients
  123. Lung cancer: investigation and staging
  124. Return of the pulmonary nodule: the radiologist's key role in implementing the 2015 BTS guidelines on the investigation and management of pulmonary nodules
  125. Pulmonary nodules and CT screening: the past, present and future
  126. The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I ...
  127. How should pulmonary nodules be optimally investigated and managed?
  128. CT screening for lung cancer: Is the evidence strong enough?
  129. Integrated Raman microscopy and auto-fluorescence imaging for fast tumour diagnosis during cancer surgery
  130. Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention
  131. Pulmonary nodules again? The 2015 British Thoracic Society guidelines on the investigation and management of pulmonary nodules
  132. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening
  133. Development of Guidelines for the Management of Pulmonary Nodules Toward Better Implementation
  134. Correction
  135. Patients’ attitudes to risk in lung cancer surgery: A qualitative study
  136. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators
  137. Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial
  138. Prediction of risk of lung cancer in populations and in pulmonary nodules: Significant progress to drive changes in paradigms
  139. Reliable EGFR mutation testing in ultrasound-guided supraclavicular lymph node fine-needle aspirates: a cohort study with diagnostic performance analysis
  140. The British Thoracic Society guidelines on the investigation and management of pulmonary nodules
  141. British Thoracic Society guidelines for the investigation and management of pulmonary nodules: accredited by NICE
  142. Screening for lung cancer
  143. Screening
  144. Plasma lipid biomarker signatures in squamous carcinoma and adenocarcinoma lung cancer patients
  145. FDG-PET/CT Imaging for Mediastinal Staging in Patients With Potentially Resectable Non–Small Cell Lung Cancer
  146. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial
  147. Non-small cell lung cancer in young adults: presentation and survival in the English National Lung Cancer Audit
  148. Author's response: What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK?
  149. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer
  150. Next steps and barriers to implementing lung cancer screening with low-dose CT
  151. Brain metastases following radical surgical treatment of non-small cell lung cancer: Is preoperative brain imaging important?
  152. What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK?
  153. The impact of the ‘hub and spoke’ model of care for lung cancer and equitable access to surgery
  154. Appetite stimulants for people with cystic fibrosis
  155. The European initiative for quality management in lung cancer care
  156. Lung cancer screening with low dose computed tomography
  157. The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening
  158. Small-Cell Lung Cancer in England: Trends in Survival and Chemotherapy Using the National Lung Cancer Audit
  159. Multidisciplinary team management in thoracic oncology: more than just a concept?
  160. The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) Response to the USPSTF Recommendations
  161. Effective lung cancer screening is possible
  162. Treatment decisions and survival for people with small-cell lung cancer
  163. CT screening for lung cancer: countdown to implementation
  164. Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009
  165. Lung cancer survival in England: trends in non-small-cell lung cancer survival over the duration of the National Lung Cancer Audit
  166. European randomized lung cancer screening trials: Post NLST
  167. Early mortality after surgical resection for lung cancer: an analysis of the English National Lung cancer audit
  168. Chronic Obstructive Pulmonary Disease and Risk of Lung Cancer: The Importance of Smoking and Timing of Diagnosis
  169. The pathological confirmation rate of lung cancer in England using the NLCA database
  170. Using socio-demographic and early clinical features in general practice to identify people with lung cancer earlier
  171. Chronic Obstructive Pulmonary Disease and Risk of Lung Cancer: The Importance of Smoking and Timing of Diagnosis
  172. The Association Between Smoking Quantity and Lung Cancer in Men and Women
  173. Authors' response
  174. Measurement Methods and Algorithms for the Management of Solid Nodules
  175. A proposed new imaging pathway for patients with suspected lung cancer
  176. The (US) National Lung Cancer Screening Trial: intensifying the debate about the introduction of screening for lung cancer
  177. What is the Most Effective Follow-up Model for Lung Cancer Patients? A Systematic Review
  178. Lung cancer: investigation and staging
  179. Authors' response
  180. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 Report
  181. Supportive Care in Respiratory Disease
  182. Authors' response
  183. How do patient and hospital features influence outcomes in small-cell lung cancer in England?
  184. Inequalities in outcomes for non-small cell lung cancer: the influence of clinical characteristics and features of the local lung cancer service
  185. CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report
  186. Diagnosis and treatment of lung cancer: summary of updated NICE guidance
  187. Lung cancer in England: Information from the National Lung Cancer Audit (LUCADA)
  188. Imaging in lung cancer: recent advances in PET-CT and screening
  189. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer
  190. Authors' response
  191. Guidelines on the radical management of patients with lung cancer
  192. Diagnosing lung cancer earlier in the UK
  193. Technical validation of an autoantibody test for lung cancer
  194. Cardiopulmonary exercise testing for the selection of patients undergoing surgery for lung cancer: friend or foe?
  195. Cytological assessment of conventional transbronchial fine needle aspiration of lymph nodes
  196. Lung cancer: investigation and staging
  197. Appetite stimulants in cystic fibrosis: a systematic review
  198. BTS statement on malignant mesothelioma in the UK, 2007
  199. NICE guidance for screening for malnutrition: implications for lung cancer services
  200. Lung cancer outcomes at a UK cancer unit between 1998–2001
  201. Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway
  202. Evaluation of the solitary pulmonary nodule: clinical management, role of CT and nuclear medicine
  203. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy
  204. Interpretation of occupational peak flow records: level of agreement between expert clinicians and Oasys-2
  205. Management of solitary pulmonary nodules: how do thoracic computed tomography and guided fine needle biopsy influence clinical decisions?
  206. Questionnaire survey of male infertility in cystic fibrosis
  207. Development of an expert system for the interpretation of serial peak expiratory flow measurements in the diagnosis of occupational asthma. Midlands Thoracic Society Research Group.
  208. How Do General Practitioners Respond to Reports of Abnormal Chest X-rays?
  209. Comparison of two new methods for the measurement of lung volumes with two standard methods
  210. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis
  211. Comparative clinical and physiological features of Maori, Pacific Islanders and Europeans with sleep related breathing disorders
  212. Effect of two types of mandibular advancement splints on snoring and obstructive sleep apnoea
  213. Pragmatics: Principals of Design and Evaluation of an Information System for a Department of Respiratory Medicine
  214. Non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease
  215. Silicosis presenting as bilateral hilar lymphadenopathy.
  216. SHORT COMMUNICATION: Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers
  217. Effect of diuretics on allergen-induced contractions of passively sensitized human bronchi in vitro.
  218. Nocturnal oxygen desaturation and exercise-induced desaturation in subjects with chronic obstructive pulmonary disease
  219. Concentrations of ceftibuten in plasma and the respiratory tract following a single 400 mg oral dose
  220. Scoring system developed for drug related morbidity
  221. Comparison of the effects of salbutamol and adrenaline on airway smooth muscle contractility in vitro and on bronchial reactivity in vivo.
  222. The concentration of sparfloxacin in lung tissues after single and multiple oral doses
  223. The levels of clarithromycin and its 14-hydroxy metabolite in the lung
  224. Cross refractoriness between sodium metabisulphite and exercise induced asthma.
  225. Effect of addition of exercise to chest physiotherapy on sputum expectoration and lung function in adults with cystic fibrosis
  226. The Effect of Sodium Transport and Calcium Channel Inhibitors on Phorbol Ester-induced Contraction of Bovine Airway Smooth Muscle
  227. Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration
  228. Laparoscopic cholecystectomy in patients with cystic fibrosis
  229. Quantitative morphology and water distribution of bronchial biopsy samples.
  230. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance.
  231. Pulmonary disposition of antimicrobial agents: methodological considerations.
  232. Bronchoalveolar distribution of cefaroxime axetil and in-vitro efficacy of observed concentrations against respiratory pathogens
  233. Concentrations of cefpodoxime in serum and bronchial mucosal biopsies
  234. The site concentrations of antimicrobial agents in the lung
  235. Microlavage: a technique for determining the volume of epithelial lining fluid.
  236. Comparative pharmacokinetic disposition of fluoroquinolones in the lung
  237. In-vitro activity and β-lactamase stability of SR 44337, a new long acting cephalosporin
  238. In-vitro susceptibility of Chlamydia pneumoniae (TWAR) to seven antibiotics
  239. The penetration of cefpirome into the potential sites of pulmonary infection
  240. Concentrations of oral lomefloxacin in serum and bronchial mucosa.
  241. Concentrations of temafloxacin in serum and bronchial mucosa
  242. Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens.
  243. Cefepime concentrations in bronchial mucosa and serum following a single 2 gram intravenous dose